Home Tirzepatide Tirzepatide vs Retatrutide
Tirzepatide vs Retatrutide
A third receptor, larger reported reductions in earlier-phase work, and no approval. Treat it as a preview.
Retatrutide is an investigational triple agonist acting at the GIP, GLP-1 and glucagon receptors. Earlier-phase results reported larger mean weight reductions than approved agents, which is why it is discussed so widely. It is not an approved product, and it is not something a legitimate program can prescribe for weight management today.
This page exists because the question comes up constantly and because it is the setting where the research-peptide market does its worst work. An unapproved investigational molecule sold online is not an early-access program; it is an unregulated substance with no prescriber and no accountability.
Comparisons between agents that have not been tested head to head are cross-trial comparisons and are weaker evidence than a randomized comparison. This page labels which is which.
What the third receptor is meant to do
Adding glucagon receptor agonism is intended to increase energy expenditure alongside the appetite effects of GIP and GLP-1 agonism. The mechanistic rationale is coherent. Mechanistic coherence has repeatedly failed to survive phase 3 in metabolic medicine, which is why approval matters.
Why the numbers should be read carefully
Earlier-phase trials enroll different populations, run for different durations and use different estimands than the 72-week programs that produced tirzepatide's figures. Comparing a phase 2 headline against a phase 3 result is not a like-for-like comparison, and the eventual approved-label figure may differ.
The only safe position today
If you want a triple agonist, the route is a clinical trial, not a website. Any vendor selling retatrutide for human use outside a trial is operating outside the prescription system entirely. See our page on counterfeit and gray-market supply for what that market actually looks like.
Tirzepatide vs Retatrutide: the shortest useful summary
Tirzepatide is a once-weekly injection titrated from 2.5 mg to a 15 mg ceiling in 2.5 mg steps at intervals of at least four weeks, producing roughly 15 to 21% mean weight reduction across the studied maintenance arms at 72 weeks and about 20% against semaglutide's 14% in the only head-to-head trial. It works while it is taken; the withdrawal evidence shows substantial regain after stopping. Compounded preparations cost from $133 a month and are not FDA-approved; brand product is approved and costs considerably more.
Those five facts decide most questions people arrive with. Everything else on this page is detail underneath them — which is worth reading before you spend $2,388 on a first year, but not worth confusing with the outline.
Tirzepatide vs Retatrutide: where to go next
If you have not chosen a program, price your expected maintenance dose with the projector rather than reading advertisements. If you have, check what it charges at 10 mg against the price-by-dose table. If you are struggling with side effects, the side-effect reference covers each one with reported frequencies and the red flags that need a clinician. And if a program has refused to name its pharmacy, the verification walkthrough explains why that single answer outranks any price difference.
Frequently asked questions
Can I get retatrutide on prescription?
Not as an approved weight-management product. Availability outside a clinical trial should be treated as a warning sign rather than an opportunity.
Will it replace tirzepatide?
Unknown. That question is answered by phase 3 results, regulatory review and long-term safety data, none of which are settled.
People also ask about tirzepatide vs retatrutide
What is tirzepatide vs retatrutide?
Tirzepatide vs retatrutide is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does tirzepatide vs retatrutide apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does tirzepatide vs retatrutide cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is tirzepatide vs retatrutide FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Sources
- SURMOUNT-1 — tirzepatide once weekly for the treatment of obesity, NCT04184622.
- SURMOUNT-5 — tirzepatide versus semaglutide in adults with obesity, NCT05822830.
- US prescribing information for tirzepatide (Zepbound and Mounjaro), Eli Lilly and Company — dosing, storage, warnings and contraindications.
- US Food and Drug Administration, human drug compounding: compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing.
- Full source ledger — every primary source with a live link, what it supports, the date we read it, and the claims we deliberately do not source.